CTLT Jan 2025 52.500 call
- Simply Wall St.
Catalent (NYSE:CTLT) investors are sitting on a loss of 47% if they invested three years ago
As an investor its worth striving to ensure your overall portfolio beats the market average. But its virtually certain...
- Business Wire
Catalent Stockholders Approve Transaction with Novo Holdings
SOMERSET, N.J., May 29, 2024--Catalent, Inc. ("Catalent," NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, today announced that, at its Special Meeting of Stockholders (the "Special Meeting") held earlier today, its stockholders voted to approve the pending transaction under which Novo Holdings A/S ("Novo Holdings") will acquire all outstanding shares of Catalent for $63.50 per share in cash (the "Merger").
- Zacks
Catalent's (CTLT) Latest Partnership to Boost Clinical Trials
Catalent's (CTLT) new tie-up to support the development and commercial manufacturing of safe, high-quality AAV gene therapies to provide life-saving treatments to cancer patients.
